Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year

blonca9
Nov 7, 2024
1 min read

CEO Neil Warma describes the unique approach to TCRs that could reduce toxicity and increase persistence compared to other programs. Plus, his view from beings a veteran to the Houston biotech scene.

Brought to you by

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight